Cargando…

Author Correction: Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins

Detalles Bibliográficos
Autores principales:	Hojjat Jodaylami, Maryam, Djaïleb, Abdelhadi, Ricard, Pierre, Lavallée, Étienne, Cellier-Goetghebeur, Stella, Parker, Megan-Faye, Coutu, Julien, Stuible, Matthew, Gervais, Christian, Durocher, Yves, Desautels, Florence, Cayer, Marie-Pierre, de Grandmont, Marie Joëlle, Rochette, Samuel, Brouard, Danny, Trottier, Sylvie, Boudreau, Denis, Pelletier, Joelle N., Masson, Jean-Francois
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602984/ https://www.ncbi.nlm.nih.gov/pubmed/34799675 http://dx.doi.org/10.1038/s41598-021-02484-9

Ejemplares similares

Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
por: Hojjat Jodaylami, Maryam, et al.
Publicado: (2021)

Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance
por: Djaïleb, Abdelhadi, et al.
Publicado: (2023)

Evaluation of the Tempo® System: Improving the Microbiological Quality Monitoring of Human Milk
por: Cayer, Marie-Pierre, et al.
Publicado: (2020)

Multiple partition Markov model for B.1.1.7, B.1.351, B.1.617.2, and P.1 variants of SARS-CoV 2 virus
por: García, Jesús Enrique, et al.
Publicado: (2022)

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
por: Wall, Emma C, et al.
Publicado: (2021)

COVID-19 outbreak trends in South Africa: A comparison of Omicron (B.1.1.529), Delta (B.1.617.2), and Beta (B.1.351) variants outbreak periods
por: Al Hasan, Syed Mahfuz, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant
por: Saha, Senjuti, et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
por: Jungnick, Sabrina, et al.
Publicado: (2021)

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
por: Wang, Pengfei, et al.
Publicado: (2021)

Comparison of the Effect of Holder Pasteurization and High-Pressure Processing on Human Milk Bacterial Load and Bioactive Factors Preservation
por: Dussault, Nathalie, et al.
Publicado: (2021)

The SARS-CoV-2 B.1.351 Variant Can Transmit in Rats But Not in Mice
por: Zhang, Cheng, et al.
Publicado: (2022)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

Effects of B.1.1.7 and B.1.351 on COVID-19 Dynamics: A Campus Reopening Study
por: Linka, Kevin, et al.
Publicado: (2021)

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
por: Dayan, Gustavo H., et al.
Publicado: (2023)

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
por: Kim, Yeong Jun, et al.
Publicado: (2021)

Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020
por: Mwenda, Mulenga, et al.
Publicado: (2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
por: Ruscheweyh, Ruth, et al.
Publicado: (2022)

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

309. Genetic Diversity and Conservation of Envelope Gene of SARS-CoV-2 and its Variants B.1.1.7, B.1.351, P.1, B.1.617.2 and B.1.1.529 with comparison with other human coronaviruses
por: Liu, Benjamin
Publicado: (2022)

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
por: Edara, Venkata Viswanadh, et al.
Publicado: (2021)

The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice
por: Chen, Qi, et al.
Publicado: (2021)

Linked Clusters of SARS-CoV-2 Variant B.1.351 — Maryland, January–February 2021
por: Feder, Kenneth A., et al.
Publicado: (2021)

Early detection of community acquired of SARS-CoV-2 lineage B.1.351 in Hong Kong
por: Tsang, Alan K.L., et al.
Publicado: (2021)

Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice
por: Yasui, Fumihiko, et al.
Publicado: (2022)

Correction: The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
por: Ruscheweyh, Ruth, et al.
Publicado: (2022)

Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021
por: Staub, Thérèse, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
por: Weiss, Anne, et al.
Publicado: (2021)

Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants
por: Xu, Xuesong, et al.
Publicado: (2022)

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
por: Zhou, Daming, et al.
Publicado: (2021)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
por: Madhi, Shabir A., et al.
Publicado: (2021)

Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)
por: Ong, Sean Wei Xiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k5h40rld9fuehd6n4j0pbl07lm